Marketing authorisation has not yet been provided for Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer. We are therefore unable to publish the guideline until this is received.
Marketing authorisation has not yet been provided for Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer. We are therefore unable to publish the guideline until this is received.